AbbVie Inc. (ABBV) Yield on Cost (YOC): 3.00%
The yield on cost (YOC) for AbbVie Inc. (ABBV) is 3.00%.
ABBV Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
3.00%
Yield on Cost for ABBV
ABBV now pays $6.74 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-09) | $60.75 | 11.09% |
| 5 years ago(2021-06-11) | $115.42 | 5.84% |
| 3 years ago(2023-06-13) | $138.31 | 4.87% |
| 1 year ago(2025-06-11) | $191.50 | 3.52% |
| Buying today(at $224.95) | $224.95 | 3.00% |
If you buy today and the dividend keeps growing
Projection: starting from today's 3.00% yield, assuming the dividend keeps compounding at its historical 6.8% rate. Boards set dividends each year, so actual figures will differ.
Today
3.00%
In 3 years
3.78%
In 5 years
4.41%
In 10 years
6.50%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for AbbVie Inc. (ABBV).
Starting Yield
3.00%
Ending YOC
8.05%
Year 15 Dividend
$18.11
Cum. Dividends Recd.
$178.28
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $6.74 | — | 3.00% | $0.00 |
| Year 1 | $7.20 | +6.81% | 3.20% | $7.20 |
| Year 2 | $7.69 | +6.81% | 3.42% | $14.89 |
| Year 3 | $8.21 | +6.81% | 3.65% | $23.10 |
| Year 4 | $8.77 | +6.81% | 3.90% | $31.87 |
| Year 5 | $9.37 | +6.81% | 4.17% | $41.24 |
| Year 6 | $10.01 | +6.81% | 4.45% | $51.25 |
| Year 7 | $10.69 | +6.81% | 4.75% | $61.94 |
| Year 8 | $11.42 | +6.81% | 5.08% | $73.36 |
| Year 9 | $12.19 | +6.81% | 5.42% | $85.55 |
| Year 10 | $13.03 | +6.81% | 5.79% | $98.58 |
| Year 11 | $13.91 | +6.81% | 6.18% | $112.49 |
| Year 12 | $14.86 | +6.81% | 6.61% | $127.35 |
| Year 13 | $15.87 | +6.81% | 7.06% | $143.22 |
| Year 14 | $16.95 | +6.81% | 7.54% | $160.17 |
| Year 15 | $18.11 | +6.81% | 8.05% | $178.28 |
AbbVie Inc. Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for AbbVie Inc. (ABBV)?
- The yield on cost (YOC) for ABBV stock is 3.00%.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael